The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance  by Hermann-Kleiter, Natascha et al.
ArticleThe Nuclear Orphan Receptor NR2F6 Is a Central
Checkpoint for Cancer Immune SurveillanceGraphical AbstractHighlightsd Genetic ablation of Nr2f6 induces immune-mediated cancer
surveillance
d Nr2f6/ mice display an immune contexture favoring anti-
tumor responses
d NR2F6 represses transcription of key cytokines in CD4+ and
CD8+ effector T cells
d NR2F6 controls the amplitude of tumor immunityHermann-Kleiter et al., 2015, Cell Reports 12, 2072–2085
September 29, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.08.035Authors
Natascha Hermann-Kleiter,
Victoria Klepsch, Stephanie Wallner, ...,
Thomas Gruber, Dominik Wolf,
Gottfried Baier
Correspondence
natascha.kleiter@i-med.ac.at (N.H.-K.),
gottfried.baier@i-med.ac.at (G.B.)
In Brief
Immune checkpoint blockade has
emerged as an effective cancer
immunotherapy strategy. Here, Hermann-
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immune surveillance, effectively
identifying an intracellular immune
checkpoint in effector T cells that governs
the amplitude of anti-cancer immunity.
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Nuclear receptor subfamily 2, group F, member 6
(NR2F6) is an orphanmember of the nuclear receptor
superfamily. Here, we show that genetic ablation of
Nr2f6 significantly improves survival in the murine
transgenic TRAMP prostate cancer model. Further-
more, Nr2f6/mice spontaneously reject implanted
tumors and develop host-protective immunological
memory against tumor rechallenge. This is paralleled
by increased frequencies of both CD4+ and CD8+
T cells and higher expression levels of interleukin 2
and interferon g at the tumor site. Mechanistically,
CD4+ and CD8+ T cell-intrinsic NR2F6 acts as a direct
repressor of the NFAT/AP-1 complex on both the
interleukin 2 and the interferon g cytokine promoters,
attenuating their transcriptional thresholds. Adoptive
transfer of Nr2f6-deficient T cells into tumor-bearing
immunocompetent mice is sufficient to delay tumor
outgrowth. Altogether, this defines NR2F6 as an
intracellular immune checkpoint in effector T cells,
governing the amplitude of anti-cancer immunity.
INTRODUCTION
Adaptive immunity together with innate effector immune cells is
established to efficiently control malignant cells. The impor-
tance of T cells for tumor cell elimination is underscored by
the observation that tumor infiltration by T cells represents a
valuable prognostic marker in different human cancer types
(Hunder et al., 2008; Hodi et al., 2010; reviewed in Motz and
Coukos, 2013). Residual T cell reactivity against malignant cells
is limited by various components of immune evasion, such as
local accumulation of immunosuppressive cell types within the
tumor microenvironment. Together this favors tumor escape
from the immune system instead of immune-mediated cancer2072 Cell Reports 12, 2072–2085, September 29, 2015 ª2015 The Acell elimination (for review, see Zitvogel et al., 2006; Zou,
2005; Motz and Coukos, 2013). Consistently, interleukin 2
(IL-2) and interferon g (IFN-g) are both additional key prognostic
indicators mirroring a protective anti-tumor immune response in
humans. High IL-2 levels thereby favor CD8+ T cell effector func-
tions (Pipkin et al., 2010). High IFN-g directly modulates both
cancer biology (e.g., by inducing tumor cell senescence)
(Schwartzentruber et al., 2011; Bedognetti et al., 2013; Brau-
mu¨ller et al., 2013; Galon et al., 2013) and induces an immune
contexture favoring continuous tumor cell elimination, a con-
cept coined ‘‘cancer immune surveillance’’ (Shankaran et al.,
2001).
Manipulating the immune system to harness anti-tumor im-
mune responses for the treatment of cancer patients has been
a major goal for many decades. Promising novel therapeutic ad-
vances blocking immune system inhibitory pathways, such as
cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and pro-
grammed cell death 1 (PD-1)/PD-1 ligand (PD-L1), are referred to
as ‘‘immune checkpoints’’ (i.e., inhibitory signaling intermediates
that control the duration and amplitude of physiological immune
responses) are successful entering into clinics (Hodi et al., 2010;
Brahmer et al., 2010; Robert et al., 2011; Hamid et al., 2013; To-
palian et al., 2012; Powles et al., 2014; Tumeh et al., 2014; Gubin
et al., 2014). In addition, adoptive T cell transfer therapy or vacci-
nation approaches are now also providing more encouraging re-
sults, especially when combined with cytokines or the above
mentioned immune checkpoint-antagonizing antibodies (van
den Eertwegh et al., 2012; Kalos and June, 2013; Restifo et al.,
2012; Kantoff et al., 2010; Bodor et al., 2012; Motz and Coukos,
2013; Schwartzentruber et al., 2011). Even though these ap-
proaches are exciting, there is an unmet medical need, as still
only a limited number of patients response to and even less pa-
tients are potentially cured by these approaches. Thus, there is a
high scientific interest to explore novel cancer immunothera-
peutic approaches with the ultimate goal to further strengthen
the patient’s immune system.
Notably, mechanistic processes that support immune-medi-
ated tissue destruction appear to be strikingly analogous inuthors
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autoimmunity and cancer. We previously demonstrated that the
nuclear receptor subfamily 2, group F, member 6 (NR2F6; also
called COUP-TFIII or Ear2) represents an important gatekeeper
of antigen receptor-induced cytokine response thresholds of
pro-inflammatory CD4+ Th17 lymphocytes (Hermann-Kleiter
et al., 2008). In these autoimmunity-promoting Th17 cells,
NR2F6 directly antagonizes the binding of the transcription fac-
tors NFAT and, particularly, retinoic acid receptor-related orphan
receptor-g-t (RORc) to the Il17 cytokine locus (Hermann-Kleiter
et al., 2012), thereby reducing central nervous system inflamma-
tion. Here, we employed various types of transplantable and
spontaneous tumor models to define the role of NR2F6 in tumor
immunology. Using these model systems, we provide strong
experimental evidence that genetic deletion of Nr2f6 is both
necessary and sufficient to induce host-protective immune
rejection of cancer.Nr2f6 deficiency leads to augmented intratu-
moral effector CD4+ and CD8+ T cell infiltration and strongly en-
hances local production of IL-2, IFN-g, and tumor necrosis fac-
tor-a (TNF-a), thereby forming an immune environment that
allows strong anti-tumor T cell responses in tumor-bearing mice.
RESULTS
Loss of NR2F6 Prolongs Survival of TRAMP Mice, an
Autochthonous Model of Prostate Cancer
We employed the murine transgenic adenocarcinoma of the
mouse prostate (TRAMP) model, in which prostate-specific
expression of SV40 large T antigen results in prostate cancer
(Greenberg et al., 1995), to evaluate the role of NR2F6 in cancer
immunity. Male TRAMP mice with different Nr2f6 genotypes
(Nr2f6+/+TRAMP and Nr2f6/TRAMP) were analyzed at week 22Figure 1. Loss of NR2F6 Prolongs Survival in the Autochthonous Pros
Secreting Infiltrating T Cells
(A) Endpoint analysis of maleNr2f6+/+TRAMP (n = 14) andNr2f6/TRAMP (n = 10) mi
Kaplan-Meier curve and statistics analyzed by the log-rank test (p = 0.0018).
(B) Weight of TRAMP urogenital (UG) tract at endpoint was not significantly differen
(NE) tumors in wild-type mice shown in triangles were absent in the Nr2f6-deficie
(C) One representative endpoint TRAMP prostate tumor with seminal vesicle me
green) mice is shown as well as one Nr2f6+/+TRAMP NE tumor (triangle, black).
(D) Phenotypic characterization of CD45+ TILs inNr2f6+/+TRAMP (black) orNr2f6/
cell percentages of total infiltrating immune cells expressing CD45+ (p = 0.02), CD
despite comparable tumor sizes.
(E) Gross examination of urogenital tracts at week 28 of Nr2f6+/+TRAMP and Nr2f6
(F and G) (F) Significantly decreased UG tracts relative to body weight (p < 0.000
(n = 21) when compared to Nr2f6+/+TRAMP mice (n = 27). Four prostate tumors w
classified as outliers due to being either too small (<0.09 g) or too large (>0.5 g).
(H) Tumor single-cell suspensions isolated fromNr2f6+/+TRAMP orNr2f6/TRAMPm
among total viable cells after gating on forward and side scatter is shown. Rep
CD45+CD8+, or CD45+CD4+ double-positive T cells isolated fromNr2f6+/+TRAMP or
the percentage of positive cells relative to parental gate.
(I) Percentage of TILs at week 28 of Nr2f6+/+TRAMP (n = 11) and Nr2f6/TRAMP
(p = 0.002) and CD45+CD4+ (p = 0.001) cells.
(J) Equal numbers of prostate tumor-infiltrating Treg cells (CD4+CD25+Foxp3+) in
(K) Percentages of total cytokine producing TILs within Nr2f6+/+TRAMP (n = 11) a
CD8+IL-2+ (p = 0.049), CD8+IFN-g+ (p = 0.001), CD4+IL-2+ (p = 0.002), and CD4+
(L) Representative cryosection ofNr2f6+/+TRAMP orNr2f6/TRAMP prostate tumors
Hoechst nuclear stain in blue, respectively. Scale bar, 50 mm.
(M) Graphical representation of increased CD4+ (p = 0.01) and CD8+ (p = 0.03) T c
four mice per genotype. Error bars represent SEM and asterisk (*) indicates statis
as calculated using Student’s t test.
2074 Cell Reports 12, 2072–2085, September 29, 2015 ª2015 The Aand 28, as well as when terminally ill. While all Nr2f6+/+TRAMP
mice had to be sacrificed due to high tumor burden latest at
week 40, 50% of Nr2f6/TRAMP mice remained alive at this
time point (Figure 1A). The majority of the primary tumor masses
were composed of atypical epithelial hyperplasia (AH); however,
26% of Nr2f6+/+TRAMP mice developed aggressive neuroendo-
crine (NE) tumors, as identified through histomorphological
analysis (Figures 1B and 1C). In contrast to Nr2f6+/+TRAMP mice
and despite a similar prostate tumor incidence, we never
observed any NE differentiation in tumors from Nr2f6/TRAMP
mice. Although tumor growth was significantly delayed in
Nr2f6/TRAMP mice, all animals had to be sacrificed at week
55. Endpoint analyses indicated an enhanced number of intratu-
moral CD45+, CD4+, and CD8+ immune cells in Nr2f6/TRAMP
mice (Figure 1D).
In order to define the mechanism underlying the observed sur-
vival benefit due to delayed tumor outgrowth in Nr2f6/TRAMP
mice, we next analyzed in detail prostate tumors at pre-defined
time points. At week 28, tumor burden (quantified by calculating
urogenital tract weight without the bladder and prostate
relative to the total body weight) was significantly reduced in
Nr2f6/TRAMP compared to Nr2f6+/+TRAMP mice (Figures 1E–
1G); notably, no differences in overall body weight could be
detected at any time point (Figures S1A–S1C). At week 28, we
observed significantly more prostate tumor-infiltrating CD4+
and CD8+ T cells in Nr2f6/TRAMP mice than in Nr2f6+/+TRAMP
mice (Figures 1H and 1I), whereas comparable numbers of
CD4+CD25+Foxp3+ tumor-infiltrating regulatory T cells could
be detected in the two genotypes (Figure 1J). Tumor-infiltrating
immune cells contained increased frequencies of CD8+IL-2+,
CD8+IFN-g+, CD4+IL-2+, and CD4+IFN-g+ T lymphocytes intate Cancer Model TRAMP Due to Enhanced Numbers of Cytokine-
ce (A) showed a significant survival benefit inNr2f6/TRAMPmice depicted by a
t betweenNr2f6+/+TRAMP andNr2f6/TRAMPmice. Aggressive neuroendocrine
nt cohort.
tastasis derived from Nr2f6+/+TRAMP (circle, black) and Nr2f6/TRAMP (square,
TRAMP (green) of prostate tumors taken at the endpoint of the experiment: higher
45+CD4+ (p = 0.009), or CD45+CD8+ (p = 0.03) are detected in Nr2f6/TRAMP
/TRAMP mice.
1) and (G) prostate weight (p < 0.0001) were observed in Nr2f6/TRAMP mice
ithin both cohorts were excluded from statistical analysis at this time point as
ice were analyzed by flow cytometry. The percentage of positively stained cells
resentative dot plots of prostate tumor-infiltrating CD45+ single-positive and
Nr2f6/TRAMPmice are depicted. Numbers adjacent to outlined areas indicate
(n = 7) mice revealed enhanced numbers of CD45+ (p = 0.006), CD45+CD8+
Nr2f6+/+TRAMP (n = 11) and Nr2f6/TRAMP (n = 7) prostate tumors.
nd Nr2f6/TRAMP (n = 7) prostate tumors: significantly enhanced numbers of
IFN-g+ (p = 0.02) cells were found within Nr2f6/TRAMP prostate tumors.
immune-fluorescence staining for the T cell markers CD4 andCD8 in green and
ell tumor infiltration in Nr2f6/mice, averaged from three fields per mouse and
tically significant differences between Nr2f6+/+TRAMP or Nr2f6/TRAMP tumors,
uthors
Nr2f6/TRAMP mice versus Nr2f6+/+TRAMP mice (Figure 1K).
Analysis by immunohistochemistry in tumors with comparable
sizes confirmed significantly higher numbers of intratumoral
CD4+ and CD8+ T cells in Nr2f6/TRAMP mice (Figures 1L and
1M). To address the role of NR2F6 in T cells within the tumor
draining lymph node (dLN), we evaluated T cell frequency, acti-
vation status, and cytokine production at week 28. Again, the
proportions of T cells that were CD45+, CD4+, CD8+, CD44+, or
IFN-g+ were significantly elevated (Figures S1D–S1G). Even
though we detected a trend toward higher intratumoral numbers
of CD4+RORc+ and gdTCR+ cells in Nr2f6/TRAMP mice versus
Nr2f6+/+TRAMP mice, the differences between the two genotypes
did not reach statistical significance (Figure S1H). Similarly, we
also observed a tendency toward larger proportions of
CD4+IL-17+, CD8+Tbet+, DX5+, and gdTCR+ cells that also did
not reach statistical significance (Figure S1I). The same readouts
were used to analyze the immune cell composition of prostate
tumors and dLNs at earlier time points (i.e., at week 22). Again,
reduced urogenital tract (UG) sizes in Nr2f6/TRAMP mice were
paralleled by increased numbers of CD45+ immune cells infil-
trating prostate tumors, and elevated numbers of CD4+IL-2+
T cells in the dLNs of Nr2f6/TRAMP mice (Figures S1J–S1M).
Taken together, these data show that the numbers of T cells in
Nr2f6/TRAMP tumor-bearing mice are increased both within the
dLNs and at the tumor site at all three time points investigated.
The enhanced production rates of IL-2 and IFN-gmay contribute
to a local immune-activated microenvironment, which, in turn,
significantly contributes to immune-mediated cancer growth
control leading to increased survival of Nr2f6/TRAMP mice.
Anti-tumor Immune Response in Nr2f6-Deficient Mice
At this point, we were not able to exclude that loss ofNr2f6 func-
tion in non-immune cells (for example, in prostate epithelial cells
within the autochthonous TRAMP tumor model) may be causally
involved in the observed alterations of tumor progression. There-
fore, we next used four different highly tumorigenic cancer cell
lines (TRAMP-C1, B16-OVA, B16-F10, and EG7) to analyze ani-
mal survival, tumor growth, and the tumor/dLN immunemicroen-
vironment; of note, all four lines are genetically wild-type for
Nr2f6. Similar to the findings from the autochthonous TRAMP
model, survival in Nr2f6-deficient mice receiving Nr2f6 wild-
type tumor cell lines was significantly enhanced. Figures 2A
and 2B demonstrate the delayed growth kinetics of subcutane-
ously injected TRAMP-C1 and B16-OVA tumors in Nr2f6-defi-
cient mice. TCRVb repertoire of wild-type and Nr2f6-deficient T
lymphocytes prior or post-B16-OVA tumor challenge from naive
or tumor dLN was investigated via clonality analysis of the indi-
vidual Vb gene families of the CDR3 region. These data indicated
unaltered clonal composition of the T cell compartment between
wild-type and Nr2f6-deficient T cells in tumor-bearing mice (Fig-
ures S2A and S2B). Furthermore, 75% of Nr2f6/mice injected
with the EG7 lymphoma cell line completely rejected EG7 tumors
and remained tumor-free throughout the entire 10-month exper-
imental period; in contrast, allNr2f6+/+ mice challenged with EG7
cells had to be sacrificed as early as day 21 post-injection
because of their high tumor burden (Figures 2C and 2D).
Of note, comparing genetic NR2F6 deletion with blocking
interaction of PD-1 with its ligand PD-L1 provides evidenceCell Repthat the observed superior anti-tumor immunity in Nr2f6/
mice is well comparable to the benefit of PD-L1 blocking therapy
in wild-type mice (employing the established protocol with
neutralizing Ab10F.9G2; Gros et al., 2014). This suggests that
NR2F6 and the PD-1/PD-L1 axis control cancer immunity to a
similar extent (Figure 2E).
As next step the B16-OVA subcutaneous (s.c.) tumor model
was used for an extensive analysis of tumor-infiltrating immune
cells at day 14 after tumor cell injection (Figure 3A), employing
a stratified CD45+/CD3+/CD4+ or CD8+ gating strategy (as out-
lined in Figures S3A and S3B). As in the autochthonous model
of prostate cancer, B16-OVA tumors grown in Nr2f6/mice ex-
hibited significantly increased numbers of tumor-infiltrating
CD45+CD3+CD4+ and CD45+CD3+CD8+ T cells, calculated at
the level of total numbers on a weight (i.e., gram) basis when
compared to wild-type mice (Figures 3B and 3C). This particular
phenotype of Nr2f6/ mice was independent of the B16-OVA
tumor size (Figure S3C). Analysis in tumors with comparable
sizes by immunohistochemistry confirmed the markedly
enhanced intratumoral CD4+ and CD8+ T cell numbers in
Nr2f6/ mice (Figures S3D and S3E), well reflecting relative
levels of tumor-infiltrating lymphocytes (TILs) (i.e., percentage
of CD45+, CD45+CD3+, CD45+CD8+, or CD45+CD4+cells; Fig-
ure S3F). Pronounced CD8+ and CD4+ T cell effector functions
in Nr2f6/ mice were found to be associated with markedly
higher expression of CD25 and PD-1 on both T cell subsets
when compared to wild-type animals (Figures 3D and 3E).
Because immunosuppressive immune cells such as Tregs,
tumor-associated macrophages (TAM), and myeloid-derived
suppressor cells (MDSCs) in the tumormicroenvironment are es-
tablished to promote T cell dysfunction and reduction of these
cells would at least in part explain increased anti-tumor immune
responses in Nr2f6/ mice, we evaluated the extend of tumor
infiltration by Treg, MDSC, and TAM (Figures 3D and 3F). In
Nr2f6/ mice, we could not detect any reduction of Treg accu-
mulation but could even observe an increased abundance of
these cells in B16-OVA tumor tissues of Nr2f6/ mice. Never-
theless, the clearly increased numbers of CD4+ and CD8+
effector TILs inNr2f6/mice outweigh this increase of immuno-
suppressive cell types, as the intratumoral ratios of Teff/Treg did
not show a significant difference between mice of both geno-
types. The ratio of CD8+ and CD4+ effector T cells to either
MDSC or TAM remain even in favor of the effector cell popula-
tions in Nr2f6/ mice.
In tumor-bearing Nr2f6/ mice, CD4+ and CD8+ tumor-infil-
trating T cell subsets expressed significantly increased amounts
of IL-2, IFN-g, and TNF-a (Figures 4A–4C). Among the dLN-deri-
ved cells, CD4+ T cells producing IL-2 and IFN-g as well as CD8+
T cells secreting IFN-g were significantly more abundant in
Nr2f6/ mice (Figures S4A–S4C) as were activated CD4+ and
CD8+ T cells (CD4+CD44hi; CD8+CD44hi) (Figure S4D). Notably,
we could not detect any obvious alterations in tumor-infiltrating
natural killer (NK) cells (DX5+), macrophages (CD11b+), or DC
subsets (CD11c+CD11b+ and CD11c+CD8a+) in Nr2f6/
compared to wild-type tumor-bearing mice (Figure S4E).
Next, the functional importance of increased cytokine se-
cretion by Nr2f6/ T cells was investigated by blocking IL-2
and IFN-g function using systemic injection of antagonizingorts 12, 2072–2085, September 29, 2015 ª2015 The Authors 2075
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Figure 2. Nr2f6/ Mice Reject Transplantable Subcutaneous Tumors
The kinetics of tumor cell growth in 8- to 12-week-old Nr2f6+/+ (black) and Nr2f6/ (green) mice bearing subcutaneously TRAMP-C1 prostate tumor cells, B16-
OVA melanoma, or EG7 lymphoma.
(A) Tumor growth curve of 1 3 106 TRAMP-C1 cells inoculated into Nr2f6+/+ (n = 5) and Nr2f6/ (n = 5) mice (ANOVA, p < 0.0001).
(B) Kinetics of 1 3 105 (n = 5) B16-OVA cells in Nr2f6+/+ (n = 17) and Nr2f6/ (n = 17) mice, which were used for subsequent analysis (ANOVA, p = 0.0017).
(C) Significant survival benefit in Nr2f6/ (n = 8) compared to Nr2f6+/+ (n = 13) mice injected with 1.5 3 105 EG7 tumor cells shown by a Kaplan-Meier curve,
statistically analyzed by a log-rank test (p = 0.0001).
(D) Kinetics of EG7 tumor cell growth in Nr2f6+/+ (n = 5) and Nr2f6/ (n = 5) mice (ANOVA, p < 0.0001). Results shown are derived from at least two independent
experiments.
(E) Tumor growth curve in Nr2f6+/+ mice (n = 9) injected s.c. with 5 3 105 B16-OVA cells and administered i.p. with 0.5 mg of an anti-mouse PD-L1 blocking
antibody as immune checkpoint inhibitor is comparable to tumor growth curve seen inNr2f6/mice (n = 8) injectedwith rat immunoglobulin G (IgG) control alone.
Summary of three independent experiments is shown, and data are expressed as the mean ± SEM, IgG control in wild-type recipients versus anti-mouse PD-L1
blocking antibody (p = 0.0019) statistically analyzed by two-way ANOVA.
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Figure 3. Enhanced Numbers of Tumor-Infiltrating T Cells in Nr2f6-Deficient Mice Bearing B16-OVA Transplantable Melanomas
(A) Gross examination of B16-OVA melanomas from Nr2f6+/+ (top) and Nr2f6/ (bottom) mice 14 days after subcutaneous injection of 1 3 105 tumor cells.
(B) Tabulation ofNr2f6+/+ (n = 6) andNr2f6/ (n = 7) B16-OVA tumor-infiltrating cells on day 14. Significantly increased absolute cell numbers of CD45+ (p = 0.01),
CD3+ (p = 0.05), CD8+ (p = 0.007), and CD4+ (p = 0.015) per 0.1 g of tumor tissue were detected in Nr2f6/ mice.
(C) Dot plots of B16-OVA tumor-infiltrating CD45+ and CD3+ cells derived from Nr2f6+/+ and Nr2f6/ tumor-bearing mice (for detailed gating strategy, see
Figure S3).
(D) Immune cell characterization of Nr2f6+/+ (n = 6) and Nr2f6/ (n = 7) B16-OVA tumor-infiltrating cells per 0.1 g of tumor tissue, gated on CD45+CD3+ positive
cells did reveal increased absolute cell numbers of CD8+CD25+ (p = 0.003); CD8+PD-1+ (p = 0.003); CD4+CD25+ (p = 0.008); CD4+PD-1+ (p = 0.001); and
CD4+CD25+Foxp3+ Treg cells (p = 0.007).
(E) Dot plots of B16-OVA tumor-infiltrating CD8+PD-1+ cells derived from Nr2f6+/+ and Nr2f6/ mice.
(F) Significantly increased absolute cell numbers of CD11b+Gr-1+ myeloid derived suppressor cells (p = 0.02), and a trend for tumor associated macrophages
(p = 0.06) (CD11b+F/80+) could be detected in tumors of Nr2f6/ (n = 7) mice.antibodies into tumor-bearing mice in vivo. These experiments
identified IFN-g as key effector cytokine at least in part explaining
enhanced anti-tumor immunity of Nr2f6/ mice, as anti-IFN-g
antibodies abrogated the tumor-protective phenotype of
Nr2f6/ animals (Figure 4D). Increased cytokine production ap-
pears to be particularly linked to tumor challenge, aswecould not
detect an enhanced steady-state cytokine-production potential
of CD4+ or CD8+ T cells in tumor-freeNr2f6/mice (Figure S5A).
The impact of Nr2f6 deficiency on tumor metastasis was next
evaluated by challenging each mouse genotype with intrave-
nously (i.v.) administered B16-F10 cells, which are known to
form lung metastases upon i.v. injection. Similar to our previous
data, formation of lung metastases was significantly reduced at
day 14 and 19 post-injection, as quantified by reduction of the
number of tumor foci in the lungs ofNr2f6-deficient mice (Figures
5A and 5B). Thus, deficiency of Nr2f6 in non-cancer cells ap-
pears to strongly enhance the anti-metastatic activity of the im-
mune system.Cell RepTo evaluate in detail whether Nr2f6-deficiency also allows in-
duction of immunological memory, we re-challenged Nr2f6/
mice that had previously rejected EG7 tumor cells (termed
‘‘memory Nr2f6/ mice’’) in parallel to 10-month-old sex-
matched EG7 tumor antigen-naive Nr2f6+/+ and Nr2f6/ mice
with a 10-fold higher EG7 tumor load than used in Figure 2. As
expected, all wild-type mice rapidly developed tumors and had
to be killed latest by day 17 post-injection. In line with our previ-
ous results, tumor outgrowth in naive Nr2f6/ mice group was
significantly delayed even with this high tumor load. In strict
contrast, only one of six memory Nr2f6/ mice had to be killed
because of tumor progression at day 41 post-injection; the other
five memory Nr2f6/ animals even rejected this higher EG7 cell
dose. Accordingly, survival of memory Nr2f6/mice (80%) was
significantly better than the survival of Nr2f6+/+ mice (0%) or the
EG7 antigen-naive Nr2f6/ cohort (20%) (Figures 5C and 5D).
In combination, these results indicate that loss of Nr2f6 in im-
mune cells strongly enhances tumor immune control. Thisorts 12, 2072–2085, September 29, 2015 ª2015 The Authors 2077
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Figure 4. Nr2f6 Expression Limits Cytokine Secretion of Tumor-Reactive T Cells
(A) Cytokine secretion of Nr2f6+/+ (n = 6) and Nr2f6/ (n = 7) TILs in tumors larger than 0.022 g revealed significant differences of absolute cell numbers per 0.1 g
tumor tissue for the following subsets CD8+IL-2+ (p = 0.01), CD8+IFN-g+ (p = 0.01), CD8+TNF-a+ (p = 0.002), CD4+IL-2+ (p = 0.002), CD4+IFN-g+ (p = 0.0006),
CD4+TNF-a+ (p = 0.0009) in Nr2f6/ mice.
(B) qRT-PCR analysis of tumors revealed enhanced Ifng (p = 0.008) as well as Il2 expression (p = 0.052) inNr2f6/mice. Results shown are derived from at least
two independent experiments.
(C) Dot plots and histograms of IFN-g and IL-2 expressing CD8+ and CD4+ tumor-infiltrating cells gated on CD45+CD3+ T cells derived fromNr2f6+/+ andNr2f6/
mice. Numbers indicate percentage of positive gated cells. Results shown are derived from at least two independent experiments. Error bars represent SEM; data
were analyzed via Student’s t test.
(D) Tumor growth wasmonitored inNr2f6/mice injected s.c. with 53 105 B16-OVAmelanoma cells and administeredwith 0.5mg of either an anti-mouse IFN-g
(n = 5) or an anti-mouse IL-2 (n = 3) neutralizing antibody or an corresponding IgG1 or IgG2a control every 3 days starting from day 1 of B16-OVA challenge.
Comparison with relevant IgG control revealed disrupted tumor protection in Nr2f6/mice treated with anti-mouse IFN-g neutralizing antibody (p = 0.006), but
not anti-mouse IL-2 neutralizing antibody (p = 0.4). Summary graphs are the mean ± SEM, statistically analyzed by two-way ANOVA.striking survival benefit for tumor-bearing Nr2f6-deficient mice
was accompanied by a host-protective induction of immunolog-
ical memory, which is well known to depend strongly on the T cell
compartment.
T Cell Intrinsic Function of NR2F6 in Cancer Immune
Surveillance
To define the role of T cells for tumor rejection in Nr2f6/mice,
we next analyzed EG7 subcutaneous tumor growth in age- and
sex-matched Rag1/ mice reconstituted with T cells derived2078 Cell Reports 12, 2072–2085, September 29, 2015 ª2015 The Afrom either Nr2f6+/+ or Nr2f6/ mice (designated as
Rag1/CD3Nr2f6+/+ and Rag1/CD3Nr2f6/, respectively).
Similar to the immunocompetent mice, tumor growth was
again strongly reduced in Rag1/CD3Nr2f6/ when compared
to Rag1/CD3Nr2f6+/+ reconstituted mice (Figures 5E and
S5B). Again, T cell numbers in the dLNs were markedly
increased (Figures 5F and S5C). Transfer experiments using
immunocompetent mice (that also have endogenous immuno-
suppressive T cells, such as Treg) similarly to the previous ex-
periments demonstrated that adoptive transfer of model tumoruthors
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Figure 5. Reduced Metastasis and Anti-Tumor Memory Depends on NR2F6 in T Cells
(A) Gross examination of representativemetastatic tumor lungs at day 14 and day 19 after tumor inoculation of eitherNr2f6+/+ mice (n = 10) orNr2f6/mice (n = 9)
i.v.-injected B16-F10.
(B) Bar chart depict numbers of lung tumor foci on day 14 (p = 0.002) and day 19 (p = 0.02) after tumor induction in Nr2f6+/+ mice and Nr2f6/ mice.
(C) Long-lasting anti-tumor memory is demonstrated after injection of EG7 tumor cells: Nr2f6/ mice (n = 6), which had received 1.5 3 105 EG7 cells subcu-
taneously at 8–12 weeks of age and rejected the primary tumor, were subsequently re-challenged after 10 months with a 10-fold higher dose of EG7 cells. In
contrast to age- and sex-matched naive Nr2f6+/+ mice (n = 6) and naive Nr2f6/mice (n = 6) controls, 80% of memory Nr2f6/mice were able to reject the 10-
fold higher tumor dose.
(D) Kaplan-Meier survival curves of age-matched naive Nr2f6+/+, naive Nr2f6/, and memory Nr2f6/ mice that received 1.5 3 106 EG7 cells subcutaneously
(p < 0.001), statistically analyzed by log-rank test.
(legend continued on next page)
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antigen-specific T cells isolated from OT-I T cell receptor (TCR)
transgenic animals crossed to the Nr2f6/ background (Fig-
ure 5G) and even polyclonal T cells from Nr2f6-deficient ani-
mals are sufficient to confer a significant tumor growth delay
(Figure 5H). Taken together, these data validate the importance
of NR2F6 as T cell-intrinsic suppressor of T cell-mediated tu-
mor growth control in vivo.
NR2F6 Represses Key Cytokine Transcription in
Effector CD4+ Th1 and CD8+ T Cells
Next, we investigate the underlying molecular mechanisms
mediating enhanced anti-tumor immune reactivity in Nr2f6/
mice and particularly increased cytokine production in Nr2f6/
CD4+ T cells in vitro. Intriguingly, the established repressor of the
antigen receptor activation threshold NR2F6 in Th17 cells (Her-
mann-Kleiter et al., 2008) is substantially upregulated upon
in vitro CD3/CD28 stimulation in CD4+ T cells (Figure 6A), indi-
cating a dynamic regulation of Nr2f6 expression as a potential
negative feedback loop limiting CD4+ T cell activation. When
culturing wild-type and Nr2f6-deficient naive CD4+ T cells under
Th1 conditions, cytokine expression pattern analyses confirmed
enhanced cytokine responses for IL-2, IFN-g and TNF-a (Figures
6B–6E). Of note, in contrast to its negative regulatory role for
effector T cell biology, NR2F6 is not required for CD4+ Treg
cell function (Figures S6A–S6F).
Similar to CD4+ T cells, expression of Nr2f6 mRNA is low in
resting CD8+ T cells, whereas its expression level is strongly
induced upon CD3/CD28 stimulation in a time-dependent
manner both in murine and human CD8+ T cells (Figures 7A
and 7B). Reminiscent to the in vivo data generated in the different
tumor models, deficiency of the murine Nr2f6 gene is associated
with significantly elevated IL-2, IFN-g, and TNF-a secretion
levels in CD8+ T cells after CD3/CD28 stimulation, as shown by
quantification of secreted cytokines as well as intracellular stain-
ing and fluorescence-activated cell sorting (FACS) (Figures 7C
and S7A). Accordingly, qRT-PCR revealed significantly
enhanced transcript levels of Il2, Ifng, and Tnfa as well as Il21,
Tbx21, Il2ra mRNA when compared to wild-type T cells (Fig-
ure 7D). Enhanced cytokine secretion was not attributable to
altered survival of Nr2f6/ CD8+ and CD4+ T cells, respectively
(Figures 7E, S6G, S6H, and S7B). Of note, Nfat2 but not Nfat1
mRNA was found to be strongly enhanced in Nr2f6-deficient
T cells (Figure 7F). NFAT2 protein levels are known to be mark-
edly induced by constitutively expressed NFAT1 upon T cell
activation (Serfling et al., 2006). By directly binding to promoters
with NFAT, where it is thought to, i.e., actively suppress(E) Enhanced tumor rejection is dependent on Nr2f6/ T lymphocytes. The kinet
Nr2f6+/+, or 13 107 CD3+Nr2f6/ T cells. The average size ofRag1/ PBS tumors
SEM; n = 8) in Rag1/CD3Nr2f6+/+ and 138 mm3 (±54 SEM; n = 8; p < 0.01) in Ra
induction in order to analyze tumor dLNs.
(F) Flow cytometry analyses revealed increased CD4+ T cell numbers in the dLNs
dLNs ofRag1/CD3Nr2f6+/+. The data are depicted as bar chart representing CD4
were statistically analyzed by Student’s t test.
(G and H) Adoptive transfer of Nr2f6/but not Nr2f6+/+ CD3+ or OT-I cells into B
Kinetics of B16-OVA tumor growth after a single therapeutic adoptive transfer
(p = 0.0083) or (H) after single transfer of 13 107CD3+ T cells again derived from ei
(p = 0.001). Data are representative of at least two independent experiments (naive
SEM statistically analyzed by two-way ANOVA.
2080 Cell Reports 12, 2072–2085, September 29, 2015 ª2015 The ANFAT/AP-1-mediated gene transcription, NR2F6 simultaneously
antagonizes the well-established amplification of Nfat2 tran-
scription, together maintaining the level of DNA-bound NFAT
proteins below what is required for robust transcriptional activa-
tion of the Il2 and Ifng promoters.
Mechanistically, we have previously established that NR2F6 is
able to directly suppress DNA binding of the activation-depen-
dent transcription factor NFAT at promoter regions within the
Il17 locus in Th17-polarized CD4+ T cells (Hermann-Kleiter
et al., 2012). Employing band-shift assays in CD8+ T cells, we
complement our recent findings by demonstrating augmented
NFAT/AP-1 binding to their bona fide consensus motif defined
within the minimal Il2 promoter region inNr2f6/ T cells (Figures
7G and S7C). Using chromatin immunoprecipitation (ChIP), we
further show that NR2F6 directly binds to the Il2 promoter in
resting wild-type CD8+ T cells; its DNA-binding capability is
reduced in a dose-dependent manner upon CD3/CD28 cross-
linking (Figures 7H and S7D). Complementary NFAT2 binding
at the Il2minimal promoter locus, as demonstrated by ChIP anal-
ysis, increases in a stimulation-dependent manner that is
strongly enhanced in the Nr2f6/ T cells (Figure S7D). Tran-
scription factor binding analysis (Matys et al., 2006) revealed
NFAT – NR2F6 DNA binding sites also at the defined distal reg-
ulatory region (1.4 kb) (Ono et al., 2007) as well as at the mini-
mal Ifng promoter. Consistently, ChIP analyses with NR2F6 and
NFAT2 revealed binding of NR2F6 to these regions in resting
cells and enhanced NFAT binding capability in activated Nr2f6-
deficient T cells (Figures S7E and S7F).
Taken together, the data indicate that T cell-intrinsic NR2F6
directly antagonizes the DNA binding capabilities of the NFAT/
AP-1 complex on the Il2 and Ifng promoters, thereby inhibiting
the antigen receptor-mediated amplitude of cytokine transcrip-
tion of these established NFAT/AP-1-dependent target genes.
Asaconsequence, enhanced IL-2and IFN-g secretion inNr2f6/
mice favors T cell-mediated cancer cell elimination,whichmay, at
least in part, explain the improved anti-tumor immunity.
DISCUSSION
Uncovering mechanisms that govern immune control of cancer
is of high clinical relevance to further develop improved im-
mune-oncological therapies (Chen and Mellman, 2013; Galon
et al., 2013; Motz and Coukos, 2013; Zitvogel et al., 2013). In
the present study, we describe that NR2F6 plays a crucial role
for effector T cell-dependent anti-tumor immunity. First, we
defined the enhanced survival of Nr2f6-deficient tumor-bearingics of tumor cell growth in Rag1/mice reconstituted with PBS, 13 107 CD3+
at 17 days was 2,034mm3 (±156 SEM; n = 5), comparedwith 1,131mm3 (±269
g1/CD3Nr2f6/ mice. One-half of the mice were killed at day 17 after tumor
of tumor-bearing Rag1/CD3Nr2f6/mice (p = 0.03) when compared to tumor
+ cells as percentage of total cells. Summary graphs show themean ±SEMand
16-OVA tumor-bearing wild-type mice significantly reduces tumor growth. (G)
of 3 3 106 OT-I donor T cells derived from either Nr2f6/ or Nr2f6+/+ mice
therNr2f6/ orNr2f6+/+mice intowild-typemice on day 7 after tumor induction
recipients nR 7/group, OT-I recipients n = 6/group); graphs show the mean ±
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Figure 6. Nr2f6 Suppresses Th1 CD4+ T Cell Activation
(A) In vitro qRT-PCR analysis of Nr2f6mRNA in wild-type CD4+ T cells during Th1 differentiation activated with anti-CD3 mAb (5 mg) and anti-CD28 mAb (1 mg) at
the indicated time points (n = 3).
(B) Bioplex technology was used to demonstrate significantly increased secretion of the pro-inflammatory cytokines IL-2 (p = 0.045), IFN-g (p = 0.047), and
TNF-a (p = 0.046) in the supernatant of in-vitro-activated Nr2f6/ versus wild-type CD4+ T cells at day 1 and day 2 of differentiation under Th1-polarizing
conditions (n = 3).
(C) In vitro qRT-PCR analysis similarly detected enhanced transcript expression levels of Il2 (p = 0.003), Ifng (p = 0.044), Tnfa (p = 0.017), but not Tbx21 (p = 0.17)
mRNA in Nr2f6/ CD4+ Th1 cells compared to Nr2f6+/+ cells upon activation with anti-CD3 (5 mg) and anti-CD28 (1 mg) at the indicated time points (n = 3).
Expression was normalized to the housekeeping gene GAPDH and presented as fold induction of unstimulated cells. Summary graphs represent the mean ± SD,
data are representative for at least two independent experiments, and statistical differences were evaluated by applying two-way ANOVA.
(D and E) (D) Analysis of IL-2 and IFN-g producing CD4+ Th1 T Nr2f6+/+ or Nr2f6/ cells by flow cytometry after 3 days (3d) of Th1 driving conditions and (E)
followed by a restimulation with anti-CD3 (5 mg) overnight (d4/re). Numbers within outlined areas indicate the percentage of cytokine-expressing cells, and one out
of three representative experiments is shown.mice and their superior immune cell composition using the pros-
tate tumor model TRAMP. Second, we validated these findings
by using various transplantable tumor models showing the sur-
vival benefit and the induction of a protective anti-tumor immune
response including long-lasting immunological memory inNr2f6-Cell Repdeficient mice. Third, we highlight that the observed anti-tumor
effects depend on NR2F6 function in T cells, as adoptive transfer
of both OT-I TCR-transgenic and even polyclonalNr2f6-deficient
T cells into tumor-bearing immunocompetent wild-type mice is
sufficient to delay tumor growth.orts 12, 2072–2085, September 29, 2015 ª2015 The Authors 2081
Albeit one cannot exclude the possibility that other immune or
non-immune cells are at least to some extent involved, consis-
tent results generated in all of our experimental approaches vali-
date the negative regulatory role of NR2F6 during T cell activa-
tion in cancer. Thus, NR2F6 acts as a bona fide intracellular
immune checkpoint in T cells. This statement is further sup-
ported by our finding that NR2F6 deletion is equally effective
than blocking PD-1/PD-L1 interaction as an established im-
mune-checkpoint mechanism.
We observed significantly elevated numbers of tumor-infil-
trating CD4+ and CD8+ T cells, as well as increased IL-2,
IFN-g, and TNF-a secretion rates in ex vivo analysis as well as
at the tumor site in Nr2f6/ tumor-bearing mice. Deficiency of
Nr2f6 thus leads to T cells with an a priori lowered TCR activation
threshold, finally resulting in enhanced cytokine secretion of IL-2
as an established key cytokine potently favoring tumor rejection
(reviewed by Liao et al., 2013). Along this line, we also observed
increased production of IFN-g by effector T cells. Importantly,
IFN-g has been shown to play a pivotal role in tumor-protective
immune responses (Weiss et al., 2011): it is critically required for
the ‘‘productive’’ immune surveillance of spontaneous malig-
nancies and chemical carcinogen methylcholanthrene (MCA)-
induced sarcomas, immune memory formation, and especially
senescence of cancer cells (Braumu¨ller et al., 2013).
Mechanistically, our data suggest that NR2F6 acts as a tran-
scriptional suppressor of NFAT/AP-1-mediated signaling in
T cells and its deletion results in enhanced sensitivity to CD3/
CD28 activation. Similar to the action of other NRs, NR2F6 ap-
pears to directly bind to sites that are otherwise occupied by
NFAT/AP-1 to prevent transcriptional activation. This supports
a model in which the balance of pre-bound NR2F6 versus
TCR-triggered NFAT/AP-1 DNA-binding-capabilities directly
dictates the outcome of, e.g., IFN-g cytokine production. As
NFAT/AP-1 transcription factors are known to bind to the Il2,
Ifng, and Tnfa promoters, it is therefore likely that NR2F6 medi-
ates its suppressive effects in tumor-reactive effector CD4+
Th1 and CD8+ T cells via this cell-intrinsic mechanism. Impor-
tantly, however, CD3/CD28-induced activation apparently leads
to an induced displacement of NR2F6 from the given cytokine
promoter, thereby promoting unopposed DNA binding of
NFAT/AP-1-complexes at the critical cytokine gene loci.
The immunological microenvironment observed in Nr2f6-defi-
cient tumor-bearing mice assemble a positive immune contex-
ture potentially supporting cancer cell rejection. This hypothesis
is strengthened by correlative clinical data showing that an
increased rate of tumor-infiltrating T cells is an important predic-
tor of clinical outcome in cancer patients (reviewed inGalon et al.,
2013; Fridman et al., 2012). Moreover, increased expression
levels of PD-1 within the TIL compartment in Nr2f6/ mice fit
to the recent observation that PD-1-expressing CD8+ T cells
are the tumor-reactive ones (Gros et al., 2014). Intriguingly,
Nr2f6 is substantially upregulated ex vivo in CD3/CD28-stimu-
latedCD4+ andCD8+Tcell cultures, respectively, indicating ady-
namic regulation of Nr2f6 expression as a negative feedback
loop. Nr2f6 gene ablation therefore results in immune response
outcomes that, albeit by adifferentmodeof action, appears remi-
niscent to theblockadeof immune tolerancesignaling inducedby
CTLA-4 or PD-1/PD-L1 (Robert et al., 2011; Hodi et al., 2010; Ha-2082 Cell Reports 12, 2072–2085, September 29, 2015 ª2015 The Amid et al., 2013; Brahmer et al., 2010; Chen and Mellman, 2013;
Fridman et al., 2012; Powles et al., 2014; Tumeh et al., 2014).
Interestingly, a correlation of NR2F6 expression and human
cancer has been observed: a compendium of data sets indicates
that Nr2f6 expression is predominately upregulated in human
ovarian cancer, colon cancer, and lymphoma (King et al., 2011;
Li et al., 2011; Eckerle et al., 2009; Ichim et al., 2011).
Genome-wide association studies and expression analysis
have linked NR2F6 to breast cancer, when compared with the
expression pattern of the other 46 human nuclear receptors (An-
toniou et al., 2010; Muscat et al., 2013). Although it is impossible
from these published data sets to determinewhether the origin of
NR2F6 expression is the malignant or the immune cell, in one
breast cancer study tumor-infiltrating T cells were isolated and
shown to have upregulated Nr2f6 expression compared to pe-
ripheral T cells (Gu-Trantien et al., 2013).
Because of the established T cell dysfunction as a conse-
quence of cancer-mediated immunosuppression, our data
strongly suggest that T cell-based therapies could significantly
benefit from modulation of this NR2F6 inhibitory signaling
pathway. Importantly, the ligand binding domain (LBD) on
NR2F6 is evolutionarily highly conserved and appears to be
essential for NR2F6 transcriptional repressor activity (Her-
mann-Kleiter et al., 2012). This potential drugability of its LBD
for a ‘‘small molecule checkpoint blockade drug’’ may provide
a rational mechanistic basis envisioning targeted manipulation
of NR2F6 in T cells as a promising intracellular checkpoint-
targeting strategy to improve the efficacy and broaden the appli-
cability of cancer immunotherapy regimens, finally enabling
prolonged patient survival.
In sum, orphan nuclear receptor NR2F6 appears to be an intra-
cellular immune checkpoint, directly repressing transcription of
cytokine genes in T cells relevant for cancer cell rejection, such
as IL-2, IFN-g, andTNF-a. Thus, in thepresenceofNR2F6effector
T cell activation is limitedwithin the tumormicroenvironment. The
exact molecular pathway by which NR2F6 impairs the transcrip-
tional amplitude of NFAT/AP-1 gene transactivation including all
target genes of NR2F6 demands further investigations.EXPERIMENTAL PROCEDURES
Mice
Nr2f6-deficient mice (Warnecke et al., 2005) backcrossed on C57BL/6 back-
ground were used. Wild-type C57BL/6 TRAMP (Tg[TRAMP]8247Ng) mice
were crossed into Nr2f6-deficient mice to generate Nr2f6/TRAMP and
Nr2f6+/+TRAMP mice. All animal experiments have been performed in accor-
dance with national and European guidelines and have been reviewed and
authorized by the committee on animal experiments (BMWFW-66.0ll/0128-
WF/V/3b/2014).
Tumor Induction and Adoptive Cell Transfer
1 3 105 B16-OVA, 3 3 105 B16-F10 cells, 1.5 3 105 EG7 cells, or 1 3 106
TRAMP-C1 cells (purchased from the ATCC, CRL-2730) were injected subcu-
taneously (s.c.) into the left flank of 8- to 12-week-oldmice. Tumormemory ex-
periments were performed via s.c. injection of 1.53 106 EG7 cells into 1-year-
oldNr2f6/mice, which rejected primary tumor challenge. Tumor growth was
monitored three times per week by measuring tumor length and width. Tumor
volume was calculated according to the following equation: 1/2(length 3
width2). For survival analysis, mice with tumors greater than the length limit
of 15 mm were sacrificed and counted as dead.uthors
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Figure 7. Nr2f6 Suppresses CD8+ T Cell Activation
(A and B)Nr2f6 expression is induced in a TCR-dependent manner in both (A) mice and (B) humanCD8+ T cells activatedwith anti-CD3 (5 mg) and anti-CD28 (1 mg)
in vitro (n = 3).
(legend continued on next page)
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Preparation of Tumor-Infiltrating Cells
Mononuclear infiltrating cells were isolated from both subcutaneous and
autochthonous tumors at the indicated time points. Briefly, tumor tissues
from sacrificed mice were prepared by mechanical disruption followed by
digestion for 45 min with collagenase D (2.5 mg/ml; Roche, 11088858001)
and DNase I (1 mg/ml; Roche, 11284932001) at 37C. Digested tissues were
incubated 5 min at 37C with EDTA (0.5 M) to prevent DC/T cell aggregates
and mashed through filters.
Statistics
Data were analyzed using Prism 5.03 software (GraphPad). Experiments were
repeated at least two or three times. Data are represented as indicated (either
mean ± SEM or ± SD) for all figure panels in which error bars are shown. The
p values were assessed using two-tailed unpaired Student’s t test, log-rank
test, or ANOVA. A p value of <0.05 was considered statistically significant:
*p < 0.05; **p < 0.01; ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2015.08.035.
AUTHOR CONTRIBUTIONS
All authors have contributed substantially to the work. S.W., K.S., S. Klepsch,
S.T., S. Kaminski, A.V., T.G., and C.P.-O. performed key experiments and/or
analyses of the data. N.H.-K. outlined and performed the overall experimental
design of tumor and memory experiments, in vitro experiments, ChIP analysis,
and qRT-PCR, prepared figures, and wrote the initial paper draft; V.K. per-
formed flow cytometry, tumor, and adoptive transfer experiments. G.B. and
D.W. provided the study conception, andG.B. provided the overall supervision
of the research at all stages.
ACKNOWLEDGMENTS
This work was supported by grants from the FFGAustrian Research Promotion
Agency (BRIDGE-842388-CBL-AIM) and FWF Austrian Science Fund (W1101-
B18, P23537-B13, P25044-B21, ‘‘Hertha-Firnberg’’ T264-B13, and ‘‘Lise-
Meitner’’ M1636-B23), the Austrian Cancer Society, Tyrol as well as the
Deutsche Forschungsgemeinschaft (DFGWO1877/1-1). We are grateful toMi-
chaela Kind and Nina Posch (both from our institute in Innsbruck) for technical
assistance.
Received: May 9, 2014
Revised: July 2, 2015
Accepted: August 11, 2015
Published: September 17, 2015(C) Bioplex technology was used to analyze the secretion of IL-2 (p = 0.0002), IFN-
CD8+ T cells at day 1 and day 2 (n = 3).
(D) qRT-PCR analysis of in-vitro-stimulatedNr2f6+/+ andNr2f6/CD8+ T cells at t
(p = 0.002), Il21 (p = 0.002), Tbx21 (p = 0.02), and Il2ra (p = 0.0006) expression lev
presented as fold induction versus unstimulated controls. Summary graphs repr
periments, and statistics were calculated using two-way ANOVA.
(E) Using FACS, CD4+ T cells were sorted from Nr2f6+/+ and Nr2f6/ mice and
(1 mg/ml). Viability was assessed by Annexin V/Propidiumiodid (PI) staining in a fl
(F) qRT-PCR analysis of in-vitro-stimulated Nr2f6+/+ and Nr2f6/ CD8+ T cells re
(G) Nr2f6+/+ and Nr2f6/ CD8+ T cells were activated with anti-CD3 (0.5 or 5 m
electromobility assays were performed for AP-1 and NFAT2. AP-1 and NFAT2 DN
was strongly enhanced in Nr2f6/ CD8+ T cells. Supershift analysis was perfor
controlled by immunoblotting of lamin B using the corresponding nuclear extrac
(H) Nr2f6 binding to the Il2 promoter was evaluated by ChIP. Therefore, eitherNr2f6
CD28 (1 mg) activated cells were used with anti-NR2F6 or IgG control, and cytokin
as percentage of input samples before immunoprecipitation.
2084 Cell Reports 12, 2072–2085, September 29, 2015 ª2015 The AREFERENCES
Antoniou, A.C., Wang, X., Fredericksen, Z.S., McGuffog, L., Tarrell, R., Sinilni-
kova, O.M., Healey, S., Morrison, J., Kartsonaki, C., Lesnick, T., et al.;
EMBRACE; GEMO Study Collaborators; HEBON; kConFab; SWE-BRCA;
MODSQUAD; GENICA (2010). A locus on 19p13modifies risk of breast cancer
in BRCA1mutation carriers and is associated with hormone receptor-negative
breast cancer in the general population. Nat. Genet. 42, 885–892.
Bedognetti, D., Spivey, T.L., Zhao, Y., Uccellini, L., Tomei, S., Dudley, M.E.,
Ascierto, M.L., De Giorgi, V., Liu, Q., Delogu, L.G., et al. (2013). CXCR3/
CCR5 pathways in metastatic melanoma patients treated with adoptive ther-
apy and IL-2. Br. J. Cancer 109, 2412–2423.
Bodor, J., Bopp, T., Vaeth, M., Klein, M., Serfling, E., Hu¨nig, T., Becker, C.,
Schild, H., and Schmitt, E. (2012). Cyclic AMP underpins suppression by reg-
ulatory T cells. Eur. J. Immunol. 42, 1375–1384.
Brahmer, J.R., Drake, C.G., Wollner, I., Powderly, J.D., Picus, J., Sharfman,
W.H., Stankevich, E., Pons, A., Salay, T.M., McMiller, T.L., et al. (2010). Phase
I study of single-agent anti-programmed death-1 (MDX-1106) in refractory
solid tumors: safety, clinical activity, pharmacodynamics, and immunologic
correlates. J. Clin. Oncol. 28, 3167–3175.
Braumu¨ller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M.,
Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013). T-help-
er-1-cell cytokines drive cancer into senescence. Nature 494, 361–365.
Chen, D.S., and Mellman, I. (2013). Oncology meets immunology: the cancer-
immunity cycle. Immunity 39, 1–10.
Eckerle, S., Brune, V., Do¨ring, C., Tiacci, E., Bohle, V., Sundstro¨m, C., Kodet,
R., Paulli, M., Falini, B., Klapper, W., et al. (2009). Gene expression profiling of
isolated tumour cells from anaplastic large cell lymphomas: insights into its
cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia
23, 2129–2138.
Fridman, W.H., Page`s, F., Saute`s-Fridman, C., and Galon, J. (2012). The im-
mune contexture in human tumours: impact on clinical outcome. Nat. Rev.
Cancer 12, 298–306.
Galon, J., Angell, H.K., Bedognetti, D., and Marincola, F.M. (2013). The contin-
uum of cancer immunosurveillance: prognostic, predictive, and mechanistic
signatures. Immunity 39, 11–26.
Greenberg, N.M., DeMayo, F., Finegold, M.J., Medina, D., Tilley, W.D., Aspi-
nall, J.O., Cunha, G.R., Donjacour, A.A., Matusik, R.J., and Rosen, J.M.
(1995). Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA
92, 3439–3443.
Gros, A., Robbins, P.F., Yao, X., Li, Y.F., Turcotte, S., Tran, E., Wunderlich,
J.R., Mixon, A., Farid, S., Dudley, M.E., et al. (2014). PD-1 identifies the pa-
tient-specific CD8+ tumor-reactive repertoire infiltrating human tumors.
J. Clin. Invest. 124, 2246–2259.
Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., deWind, A., Ravoet,
M., LeBuanec,H., Sibille,C.,Manfouo-Foutsop,G., et al. (2013).CD4+ follicularg (p = 0.03), and TNF-a (p = 0.016) in the supernatant of in vitro activatedmurine
he indicated time points revealed enhanced Il2 (p = 0.0003), Ifng (p = 0.02), Tnfa
els (n = 3). Expression was normalized to the housekeeping gene GAPDH and
esent the mean ± SD, data are representative of at least two independent ex-
stimulated in vitro with plate-bound anti-CD3 (5 mg/ml) plus soluble anti-CD28
ow cytometer after 48 hr.
vealed enhanced Nfat2 (p = 0.015) expression levels (n = 3).
g) and anti-CD28 (1 mg) for 20 hr in vitro, nuclear extracts were isolated, and
A binding is induced in an anti-CD3mAb concentration-dependent manner and
med by using antibodies against c-fos and NFAT2 as indicated. Loading was
ts (Figure S7C). One representative experiment out of three is shown.
+/+ orNr2f6/CD8+ resting or activated for 20 hr with anti-CD3 (5 mg) and anti-
e promoter sequence was quantified by real-time PCR. The data are presented
uthors
helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123,
2873–2892.
Gubin, M.M., Zhang, X., Schuster, H., Caron, E., Ward, J.P., Noguchi, T., Iva-
nova, Y., Hundal, J., Arthur, C.D., Krebber, W.J., et al. (2014). Checkpoint
blockade cancer immunotherapy targets tumour-specific mutant antigens.
Nature 515, 577–581.
Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., Wolchok,
J.D., Hersey, P., Joseph, R.W., Weber, J.S., et al. (2013). Safety and tumor re-
sponses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369,
134–144.
Hermann-Kleiter, N., Gruber, T., Lutz-Nicoladoni, C., Thuille, N., Fresser, F.,
Labi, V., Schiefermeier, N., Warnecke, M., Huber, L., Villunger, A., et al.
(2008). The nuclear orphan receptor NR2F6 suppresses lymphocyte activation
and T helper 17-dependent autoimmunity. Immunity 29, 205–216.
Hermann-Kleiter, N., Meisel, M., Fresser, F., Thuille, N., Mu¨ller, M., Roth, L.,
Katopodis, A., and Baier, G. (2012). Nuclear orphan receptor NR2F6 directly
antagonizes NFAT and RORgt binding to the Il17a promoter. J. Autoimmun.
39, 428–440.
Hodi, F.S., O’Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen,
J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. (2010).
Improved survival with ipilimumab in patients with metastatic melanoma.
N. Engl. J. Med. 363, 711–723.
Hunder, N.N., Wallen, H., Cao, J., Hendricks, D.W., Reilly, J.Z., Rodmyre, R.,
Jungbluth, A., Gnjatic, S., Thompson, J.A., and Yee, C. (2008). Treatment of
metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
N. Engl. J. Med. 358, 2698–2703.
Ichim, C.V., Atkins, H.L., Iscove, N.N., andWells, R.A. (2011). Identification of a
role for the nuclear receptor EAR-2 in the maintenance of clonogenic status
within the leukemia cell hierarchy. Leukemia 25, 1687–1696.
Kalos, M., and June, C.H. (2013). Adoptive T cell transfer for cancer immuno-
therapy in the era of synthetic biology. Immunity 39, 49–60.
Kantoff, P.W., Schuetz, T.J., Blumenstein, B.A., Glode, L.M., Bilhartz, D.L.,
Wyand, M., Manson, K., Panicali, D.L., Laus, R., Schlom, J., et al. (2010). Over-
all survival analysis of a phase II randomized controlled trial of a Poxviral-based
PSA-targeted immunotherapy in metastatic castration-resistant prostate can-
cer. J. Clin. Oncol. 28, 1099–1105.
King, E.R., Tung, C.S., Tsang, Y.T.M., Zu, Z., Lok, G.T.M., Deavers, M.T.,
Malpica, A., Wolf, J.K., Lu, K.H., Birrer, M.J., et al. (2011). The anterior gradient
homolog 3 (AGR3) gene is associated with differentiation and survival in
ovarian cancer. Am. J. Surg. Pathol. 35, 904–912.
Li, X.-B., Jiao, S., Sun, H., Xue, J., Zhao,W.-T., Fan, L., Wu, G.-H., and Fang, J.
(2011). The orphan nuclear receptor EAR2 is overexpressed in colorectal
cancer and it regulates survivability of colon cancer cells. Cancer Lett. 309,
137–144.
Liao,W., Lin, J.-X., and Leonard,W.J. (2013). Interleukin-2 at the crossroads of
effector responses, tolerance, and immunotherapy. Immunity 38, 13–25.
Matys, V., Kel-Margoulis, O.V., Fricke, E., Liebich, I., Land, S., Barre-Dirrie, A.,
Reuter, I., Chekmenev, D., Krull, M., Hornischer, K., et al. (2006). TRANSFAC
and its module TRANSCompel: transcriptional gene regulation in eukaryotes.
Nucleic Acids Res. 34, D108–D110.
Motz, G.T., and Coukos, G. (2013). Deciphering and reversing tumor immune
suppression. Immunity 39, 61–73.
Muscat, G.E.O., Eriksson, N.A., Byth, K., Loi, S., Graham, D., Jindal, S., Davis,
M.J., Clyne, C., Funder, J.W., Simpson, E.R., et al. (2013). Research resource:
nuclear receptors as transcriptome: discriminant and prognostic value in
breast cancer. Mol. Endocrinol. 27, 350–365.
Ono, M., Yaguchi, H., Ohkura, N., Kitabayashi, I., Nagamura, Y., Nomura, T.,
Miyachi, Y., Tsukada, T., and Sakaguchi, S. (2007). Foxp3 controls regulatory
T-cell function by interacting with AML1/Runx1. Nature 446, 685–689.Cell RepPipkin, M.E., Sacks, J.A., Cruz-Guilloty, F., Lichtenheld, M.G., Bevan, M.J.,
and Rao, A. (2010). Interleukin-2 and inflammation induce distinct transcrip-
tional programs that promote the differentiation of effector cytolytic T cells. Im-
munity 32, 79–90.
Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C., Bellmunt,
J., Burris, H.A., Petrylak, D.P., Teng, S.L., et al. (2014). MPDL3280A (anti-PD-
L1) treatment leads to clinical activity in metastatic bladder cancer. Nature
515, 558–562.
Restifo, N.P., Dudley, M.E., and Rosenberg, S.A. (2012). Adoptive immuno-
therapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12,
269–281.
Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Weber, J., Garbe, C.,
Lebbe, C., Baurain, J.F., Testori, A., Grob, J.J., et al. (2011). Ipilimumab plus
dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med.
364, 2517–2526.
Schwartzentruber, D.J., Lawson, D.H., Richards, J.M., Conry, R.M., Miller,
D.M., Treisman, J., Gailani, F., Riley, L., Conlon, K., Pockaj, B., et al. (2011).
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
N. Engl. J. Med. 364, 2119–2127.
Serfling, E., Chuvpilo, S., Liu, J., Ho¨fer, T., and Palmetshofer, A. (2006).
NFATc1 autoregulation: a crucial step for cell-fate determination. Trends Im-
munol. 27, 461–469.
Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J.,
and Schreiber, R.D. (2001). IFNgamma and lymphocytes prevent primary
tumour development and shape tumour immunogenicity. Nature 410, 1107–
1111.
Topalian, S.L., Drake, C.G., and Pardoll, D.M. (2012). Targeting the PD-1/B7-
H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24,
207–212.
Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert,
L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014). PD-1
blockade induces responses by inhibiting adaptive immune resistance. Nature
515, 568–571.
van den Eertwegh, A.J., Versluis, J., van den Berg, H.P., Santegoets, S.J., van
Moorselaar, R.J., van der Sluis, T.M., Gall, H.E., Harding, T.C., Jooss, K.,
Lowy, I., et al. (2012). Combined immunotherapy with granulocyte-macro-
phage colony-stimulating factor-transduced allogeneic prostate cancer cells
and ipilimumab in patients with metastatic castration-resistant prostate can-
cer: a phase 1 dose-escalation trial. Lancet Oncol. 13, 509–517.
Warnecke, M., Oster, H., Revelli, J.P., Alvarez-Bolado, G., and Eichele, G.
(2005). Abnormal development of the locus coeruleus in Ear2(Nr2f6)-deficient
mice impairs the functionality of the forebrain clock and affects nociception.
Genes Dev. 19, 614–625.
Weiss, G.R., Grosh, W.W., Chianese-Bullock, K.A., Zhao, Y., Liu, H., Slingluff,
C.L., Jr., Marincola, F.M., and Wang, E. (2011). Molecular insights on the pe-
ripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin)
administration for the treatment of metastatic melanoma. Clin. Cancer Res.
17, 7440–7450.
Zitvogel, L., Tesniere, A., and Kroemer, G. (2006). Cancer despite immunosur-
veillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6,
715–727.
Zitvogel, L., Galluzzi, L., Smyth, M.J., and Kroemer, G. (2013). Mechanism of
action of conventional and targeted anticancer therapies: reinstating immuno-
surveillance. Immunity 39, 74–88.
Zou, W. (2005). Immunosuppressive networks in the tumour environment and
their therapeutic relevance. Nat. Rev. Cancer 5, 263–274.orts 12, 2072–2085, September 29, 2015 ª2015 The Authors 2085
